Immunotech Biopharm Balance Sheet Health
Financial Health criteria checks 4/6
Immunotech Biopharm has a total shareholder equity of CN¥387.8M and total debt of CN¥321.2M, which brings its debt-to-equity ratio to 82.8%. Its total assets and total liabilities are CN¥1.0B and CN¥650.0M respectively.
Key information
82.8%
Debt to equity ratio
CN¥321.22m
Debt
Interest coverage ratio | n/a |
Cash | CN¥266.88m |
Equity | CN¥387.77m |
Total liabilities | CN¥650.02m |
Total assets | CN¥1.04b |
Financial Position Analysis
Short Term Liabilities: 6978's short term assets (CN¥316.2M) exceed its short term liabilities (CN¥174.5M).
Long Term Liabilities: 6978's short term assets (CN¥316.2M) do not cover its long term liabilities (CN¥475.5M).
Debt to Equity History and Analysis
Debt Level: 6978's net debt to equity ratio (14%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 6978's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6978 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6978 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 11.3% each year.